1. Home
  2. Directory
  3. New York
  4. Mount Kisco
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1780143792

DR. JENNA RACHEL TAUBER MD
Prescription History 1780143792
Ophthalmology - Cornea and External Diseases Specialist in Mount Kisco, NY

NPI Status: Active since March 19, 2019

Contact Information

185 KISCO AVENUE
SUITE 500
MOUNT KISCO, NY
ZIP 10549
Phone: (914) 666-4939
Fax: (914) 242-7209

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JENNA RACHEL TAUBER MD, an active Cornea and External Diseases Specialist specialist practicing in Mount Kisco, NY. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 353 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisolone Acetate, which accounts for 109 claims alone.

Medication Index

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 17
30-Day Fills 27.2
Days Supply 802
NY State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills105.3
Peer Average Days Supply3,022
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,658.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$97.54

State Avg Cost Per Claim

$70.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 39
30-Day Fills 57.4
Days Supply 1,720
NY State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills175.1
Peer Average Days Supply5,241
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $810.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.78

State Avg Cost Per Claim

$32.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Ketorolac Tromethamine

Generic Formulation: Ketorolac TromethamineSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 52
30-Day Fills 71.5
Days Supply 2,043
NY State Average Benchmarks
Peer Average Claims99.0
Peer Average 30-Day Fills117.5
Peer Average Days Supply2,998
Conservative Utilization

This provider writes prescriptions for this formulation 47.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,286.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.74

State Avg Cost Per Claim

$26.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Therapeutic Applications

This medication is used to temporarily relieve itching eyes caused by seasonal allergies. It is also used to prevent and treat eye swelling due to a certain type of eye surgery (cataract removal). Ketorolac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking certain natural substances in your body to reduce pain and swelling.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 80
30-Day Fills 112.6
Days Supply 3,119
NY State Average Benchmarks
Peer Average Claims149.0
Peer Average 30-Day Fills254.5
Peer Average Days Supply7,268
Conservative Utilization

This provider writes prescriptions for this formulation 46.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,288.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.11

State Avg Cost Per Claim

$20.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 281
NY State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills76.3
Peer Average Days Supply1,280
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $651.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.30

State Avg Cost Per Claim

$36.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Ofloxacin

Generic Formulation: OfloxacinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 25
30-Day Fills 30.1
Days Supply 801
NY State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply1,731
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.8% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $458.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.33

State Avg Cost Per Claim

$20.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Therapeutic Applications

This medication is used to treat eye infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Olopatadine Hcl

Generic Formulation: Olopatadine HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 305
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills50.4
Peer Average Days Supply1,378
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.94

State Avg Cost Per Claim

$43.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antihistamine used to treat itching and redness in the eyes due to allergies. This medication is not recommended for the treatment of eye irritation due to wearing contact lenses.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 109
30-Day Fills 142.4
Days Supply 3,862
NY State Average Benchmarks
Peer Average Claims135.0
Peer Average 30-Day Fills176.5
Peer Average Days Supply4,637
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,954.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.63

State Avg Cost Per Claim

$52.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JENNA RACHEL TAUBER MD provides transparency into local medical care patterns within Mount Kisco, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Cornea and External Diseases Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.